Replies to post #20261 on Marker Therapeutics Inc (MRKR)

[Marv79]

My understanding after being involved with the company on a very long term basis, Glynn has learned to temper his enthusiasm and received some coaching from major investors. Additionally, the company has enlisted Bonfiglio to execute the clinical trials. As a result, there is reasonable potential to assume this top line revenue can be realized in 2018, very good news. Wilson would not communicte the above unless all was going very well in the trials. Given all the execution and good news over the last six months, it is time to be proactive and positive and not question CEO communications to the market. I really do not think you are privy to any schedule for TPIV, I think I will listen to Wilson/Binfiglio.

[erg61]

Or maybe even 2020 according to his past track record. I don't want to take anything away from him because he has been dedicated and determined for many years. I have been a stock holder and a follower for at least 7 years. With that said, he is the most optimistic person I know of and because of his strong belief in TPIV, he at times gets ahead of himself. Eventually this company will pay off for those who need the science to cure their illnesses and for the stock holders who have been patiently following TPIV.
All one has to do is look at the facts that have been accomplished recently. Look at the collaborations with the many world renowned
institutions namely, Mayo Clinic, Memorial Sloan Kettering Hospital and the DOD. There has been much progress made over the years and with patience this company will produce positive results that will ultimately lead to a buyout. IMHO.
Just my .02??